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Objective To evaluate the efficacy and safety of
secukinumab, a fully human, anti-interleukin (IL)-17A
monoclonal antibody, in patients with psoriatic arthritis
(PsA).
Methods 42 patients with active PsA fulfilling
ClASsification for Psoriatic ARthritis (CASPAR) criteria
were randomly assigned (2:1) to receive two intravenous
secukinumab doses (10 mg/kg; n=28) or placebo (n=14)
3 weeks apart. The primary endpoint was the proportion
of American College of Rheumatology (ACR) 20
responses at week 6 for secukinumab versus placebo
(one-sided p<0.1).
Results Primary endpoint: ACR20 responses at week 6
were 39% (9/23) for secukinumab versus 23% (3/13)
for placebo (p=0.27). ACR20 responses were greater
with secukinumab versus placebo at week 12 (39%
(9/23) vs 15% (2/13), p=0.13) and week 24 (43%
(10/23) vs 18% (2/11), p= 0.14). At week 6, ‘good’
European League Against Rheumatism response was
seen in 21.7% (5/23) secukinumab versus 9.1% (1/11)
placebo patients. Compared with placebo at week 6,
significant reductions were observed among
secukinumab recipients for C reactive protein (p=0.039),
erythrocyte sedimentation rate (p=0.038), Health
Assessment Questionnaire Disability Index (p=0.002)
and Short Form Health Survey (SF-36; p=0.030) scores.
The overall adverse event (AE) frequency was
comparable between secukinumab (26 (93%)) and
placebo (11 (79%)) recipients. Six serious AEs (SAEs)
were reported in four secukinumab patients and one
SAE in one placebo patient.
Conclusions Although the primary endpoint was not
met, clinical responses, acute-phase reactant and quality
of life improvements were greater with secukinumab
versus placebo, suggesting some clinical benefit.
Secukinumab exhibited satisfactory safety. Larger clinical
trials of secukinumab in PsA are warranted.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory joint
disorder associated with synovitis, enthesitis and, in
the majority of patients, classical psoriatic skin lesions.
It affects 0.3%–1% of the general population and up
to 30% of patients with psoriasis.1 2 The natural
course of PsA involves significant disability and
reduced life expectancy.3 4 The primary goals of treat-
ment are to arrest disease progression, to improve
quality of life and ultimately to achieve clinical remis-
sion.5 Therapeutic interventions for PsA include con-
ventional disease-modifying antirheumatic drugs
(DMARDs) and biological agents that target the
proinflammatory cytokine tumour necrosis factor α
(TNFα).6 7 Rigorous use of these agents has improved
the management of PsA in recent years; however, sig-
nificant unmet clinical needs remain. These include
limited drug tolerance; non-responsiveness, partial
responsiveness or development of therapeutic resist-
ance to existing agents; and, in some patients, lack of
prevention of long-term structural damage.
Synovial tissue from PsA patients is characterised
by increased levels of interleukin (IL)-17A produced
by T cells and possibly by non-T cells.8–10 In PsA,
IL-17A is functionally active, often operating in
synergy with adjacent inflammatory cytokines, and it
regulates the expression of cytokines and matrix
metalloproteinases, which promote pathogenesis.11
An IL-17-inducible gene signature identified in kerati-
nocytes from patients with psoriasis vulgaris skin
lesions includes chemoattractants, such as IL-8 and
chemokine (C–C motif) ligand 20 (CCL20), and
innate molecules, such as S100 calcium-binding
proteins A8 and A9 (S100A8/A9) and human
β-defensin-2 (hBD-2; also known as β-defensin-4).12
Serum hBD-2 has recently been suggested to be a
useful surrogate marker for disease activity in psoria-
sis.13 Moreover, lesional hBD-2 mRNA has been
found to be significantly downregulated upon treat-
ment with etanercept14 and secukinumab.15
Secukinumab is a fully human, high-affinity,
anti-IL-17A monoclonal antibody that binds to and
neutralises IL-17A. In proof-of-concept and
phase II trials, secukinumab showed therapeutic
potential in rheumatoid arthritis, moderate-to-
severe plaque psoriasis, non-infectious uveitis and
ankylosing spondylitis.15–18 In the present study,
we evaluated the efficacy and safety of secukinumab
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in patients with active, moderate-to-severe PsA. In addition, we
sought to explore the relationship between serum hBD-2 and
clinical responses to secukinumab in this patient population.
MATERIALS AND METHODS
Study design and patient population
This was a randomised, double-blind, placebo-controlled, multi-
centre, 24-week, phase IIa study of secukinumab (two intraven-
ous doses of 10 mg/kg given 21 days apart) for the treatment of
active PsA. The study was conducted from 18 March 2009 to
22 December 2010, at 11 centres in three countries: Germany,
The Netherlands and the UK.
Male and female patients aged 18–65 years fulfilling the follow-
ing criteria were eligible for enrolment: moderate-to-severe PsA
diagnosed according to the ClASsification for Psoriatic ARthritis
(CASPAR) criteria19 and involvement of three or more swollen and
tender peripheral joints; Physician’s Global Assessment score ≥40,
based on a visual analogue scale (VAS 0–100 mm); inflammatory
pain score ≥40 (VAS 0–100 mm); disease inadequately controlled
on ≥1 DMARD given for ≥3 months at the maximum tolerated
dose; and a rheumatoid factor level ≤100 IU with a negative cyclic
citrullinated protein ELISA result. Key exclusion criteria included
the presence of arthritis fulfilling the classification criteria for
rheumatoid arthritis or a seronegative spondyloarthropathy fulfill-
ing the modified New York classification criteria for ankylosing
spondylitis; history or presence of malignancy; positive blood test
result for hepatitis B, hepatitis C or HIV infection; active systemic
infection within 2 weeks of screening; severe, progressive or
uncontrolled concomitant diseases; kidney impairment; or severe
cardiac disease. Considerations regarding concomitant medications
are summarised in the online supplementary appendix.
Informed consent was obtained from each patient before ran-
domisation. The study was conducted according to the ethical
principles of the Declaration of Helsinki and approved by the
Independent Ethics Committee or Institutional Review Board
for each centre. The study is registered with ClinicalTrials.gov
(#NCT00809614), and the protocol is available from the
sponsor.
Study procedures and evaluations
Forty-two patients were randomly assigned (2:1) to receive two
doses of either secukinumab 10 mg/kg (n=28) or placebo
(n=14). Secukinumab or placebo was administered intraven-
ously at baseline (day 1) and on day 22. Patients returned on
day 2 to provide a 24-hour post-infusion blood sample for phar-
macokinetic and biomarker (mRNA and cytokine) analyses,
then weekly (days 8 and 15) for response assessments and safety
evaluations. On day 22, patients received the second infusion of
secukinumab 10 mg/kg or placebo and then were observed for
up to 21 weeks.
Novartis generated the randomisation list using a validated
system. A quality assurance group reviewed the randomisation
list, which was locked following approval. Patients and investiga-
tors were blinded to the treatment allocation, and the appear-
ance of the placebo was identical to that of secukinumab to
maintain blinding.
Disease assessments (tender and swollen joints) were made
according to American College of Rheumatology (ACR) response
criteria,20 Psoriatic Arthritis Response Criteria (PsARC),21 with
distal interphalangeal joints included in the joint count, and
the Disease Activity Score 28 (DAS28).22 The investigator or a
designated qualified individual performed the joint counts. Joint
tenderness and swelling were graded present (1) or absent (0).
Patient and physician global assessments of disease activity were
recorded on a 0–100 mm VAS, and a similar scale was used to
assess pain intensity (VAS 0–100 mm). Other assessments
included the European League Against Rheumatism (EULAR)
response criteria, defined using the DAS28 (good responders
were patients with an improvement in DAS28 from baseline of
>1.2 and a present score of ≤3.2; moderate responders had an
improvement of >0.6 to ≤1.2 and a present score of >3.2 and
≤5.1; non-responders had an improvement of ≤0.6 and a
present score of >5.1);23 the Psoriasis Area and Severity Index
(PASI 0 (no disease) to 72 (maximal disease)),24 which assessed
the extent of psoriasis on four body surface areas (head, trunk,
upper limbs and lower limbs) and the degree of plaque erythema,
scaling and thickness; the Maastricht Ankylosing Spondylitis
Enthesitis Score (MASES)25 26 and the Spondyloarthritis
Research Consortium of Canada (SPARCC) score,27 which evalu-
ated 13 and 18 enthesis sites, respectively; and the Leeds
Dactylitis Index (LDI) basic score.28 The LDI basic score was
derived by measuring the ratio of the circumference of the
affected digit to the circumference of the digit on the opposite
hand or foot, using a minimum difference of 10% to define a
dactylitic digit; the ratio of the circumference was multiplied by a
tenderness score (1 for tender, 0 for non-tender). C reactive
protein (CRP) levels were measured with a high-sensitivity assay.
Erythrocyte sedimentation rate (ESR) was measured locally using
a standard kit supplied by the central lab. Patients’ health-related
quality of life (HRQoL) was assessed using two validated ques-
tionnaires: the Short Form Health Survey (SF-36)29 and the
Health Assessment Questionnaire Standard Disability Index
(HAQ-DI).30
Study endpoints
The primary endpoint was the proportion of patients achieving
an ACR20 response at week 6, defined by the following three
conditions: ≥20% improvement in the number of tender joints
(based on 68 joints), ≥20% improvement in the number of
swollen joints (based on 66 joints) and ≥20% improvement in
three of five additional domains (Patient’s Global Assessment,
Physician’s Global Assessment, pain, disability measured by the
HAQ and acute-phase reactant measured by CRP). The result
was considered statistically significant if the one-sided p value
was <0.1.
Key secondary endpoints were safety and tolerability at weeks
1, 2, 6, 8, 12, 16 and 24; the proportion of patients achieving
ACR20, ACR50 and ACR70 responses (with the latter two
defined in a manner similar to the ACR20 response but requir-
ing improvements of ≥50% and ≥70%, respectively); PsARC;
EULAR-defined response based on DAS28 score;23 proportion
of patients in EULAR-defined remission (DAS28 score ≤2.6)31;
MASES score; SPARCC score; LDI basic score; PASI score; and
HRQoL by SF-36 and HAQ-DI. Post hoc analyses included
treatment group comparisons of changes in CRP and ESR from
baseline to week 6 and a subgroup analysis of ACR20/50/70
response for TNFα inhibitor (TNFi)-naive versus TNFi pre-
exposed patients at week 6. An exploratory analysis was con-
ducted to assess hBD-2 levels at weeks 0 and 6. Anti-drug anti-
body testing was performed using two validated, independent
capture assays (screening and confirmation).
Statistical methods are presented in the online supplementary
appendix.
RESULTS
Patient disposition and baseline characteristics
Thirty-five (83.3%) of the 42 randomised patients completed
the study (secukinumab, 25/28; placebo, 10/14) (figure 1);
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3 patients (10.7%) on secukinumab and 4 patients (28.6%) on
placebo discontinued prematurely (because of lack of efficacy/
withdrawal of consent). Among the 28 patients randomised to
secukinumab and the 14 randomised to placebo, 4 secukinumab
patients (2 inclusion/exclusion criteria violations, 1 serious
adverse event (SAE) and 1 disallowed medication prior to week
6) and 1 placebo patient (inclusion/exclusion criteria violations)
were excluded from the efficacy analysis because of protocol
violations (per-protocol analysis), leaving a total of 24 secukinu-
mab and 13 placebo patients for the efficacy analysis.
Demographics and baseline characteristics were balanced
between groups, with the exception of the female to male ratio,
which was close to 2:1 and thus higher than expected for a
European PsA population. The majority of the patients were
Caucasian (93%) (table 1). Prevalent psoriasis, prior TNFi
exposure and concomitant therapy with DMARDs were
reported for 23, 10 and 13 patients on secukinumab and for
11, 3 and 6 patients on placebo, respectively.
Efficacy
The ACR20 response rate at week 6 was 39% (9/23) for patients
who received secukinumab versus 23% (3/13) for those who
received placebo. Although numerically higher for secukinumab,
the ACR20 response rate was not statistically different from
placebo (95% CI 0.38 to 15.15, p=0.27) and the primary end-
point was not met. When ACR20 and ACR50 responses were
present, onset was rapid in secukinumab-treated patients, occur-
ring as early as week 2. At week 6, higher hurdle endpoints for
secukinumab versus placebo were ACR50 (17% (4/23) vs 8%
(1/13), p=0.39) and ACR70 (9% (2/23) vs 0% (0/23), p=0.40)
responses and PsARC (43% (10/23) vs 38% (5/13), p=0.53)
(figure 2). ACR20 responses in secukinumab-treated patients
were maintained over time (39% (9/23) at week 12 and 43%
(10/23) at week 24/end of study).
No clinically relevant differences between secukinumab- and
placebo-treated patients were noted for the mean DAS28 score
over time (data not shown). At week 6, good EULAR response
was seen in 21.7% (5/23) of the patients treated with secukinu-
mab versus 9.1% (1/11) treated with placebo, and at week 12,
good response was seen in 33.3% (7/21) versus 18.2% (2/11) of
patients, respectively. At week 6, remission (DAS28 score ≤2.6)
was achieved in 21.7% (5/23) of the patients treated with secu-
kinumab versus 9.1% (1/11) treated with placebo; at week 12,
remission was achieved in 23.8% (5/21) of secukinumab-treated
patients versus 9.1% (1/11) of placebo-treated patients.
A decrease in median PASI score from baseline was noted in
patients treated with secukinumab up to week 24, whereas no
decrease was seen in placebo patients. However, PASI scores at
baseline were very low (median 2.1 for secukinumab and 2.0
for placebo), and, unsurprisingly, no meaningful interpretation
of changes following secukinumab therapy was possible (see
online supplementary table S1). Likewise, SPARCC and MASES
enthesitis scores were low at baseline and no further decrease
could be demonstrated following treatment with secukinumab
(data shown in online supplementary table S1). LDI basic scores
were available for 10 patients (6 on secukinumab). No or
minimal changes only were observed between the mean scores
at baseline and the mean scores reported for weeks 6 and 12
(see online supplementary table S1).
Results from two QoL outcome measurements are provided
in table 2. Statistically significant differences between the secuki-
numab and the placebo groups were observed at weeks 6 and
12 for percentage change from baseline HAQ-DI score, for per-
centage of patients with HAQ-DI score reduction from baseline
>0.3 and for the SF-36 physical component.
Post hoc analyses
CRP and ESR changes from baseline to week 6 are depicted in
figure 3A,B. Comparisons between the secukinumab and the
placebo arms yielded statistically significant differences for both
of these acute-phase parameters (CRP: p=0.039; ESR:
p=0.038). A subgroup analysis evaluated ACR20, ACR50 and
ACR70 responses at week 6 for TNFi-naive versus prior
TNFi-exposed patients. Among patients with prior TNFi
therapy (n=13), 1/10 (10%) patients treated with secukinumab
and 1/3 (33.3%) patients treated with placebo achieved an
ACR20 response. In contrast, in the TNFi-naive group (n=23),
8/13 (62%) patients treated with secukinumab achieved an
ACR20 response versus 2/10 (20%) patients treated with
placebo (figure 3C).
Exploratory biomarker analysis
hBD-2 concentrations were available from 34 patients (24 on
secukinumab and 10 on placebo) at baseline and post-treatment,
and kinetics are depicted in figure 3A,B. Marked reductions of
hBD-2 serum concentrations were seen in a majority of
secukinumab-treated patients, whereas only minor and random
changes were noticeable for the placebo group. Reductions were
most prominent for the patients with high pre-treatment hBD-2
concentrations. Comparisons between the secukinumab and the
placebo arms demonstrated a highly significant advantage for
secukinumab for hBD-2 reductions from baseline (p=0.0009).
Summary statistics for hBD-2 at baseline and week 6 are shown
in online supplementary table S2.
Figure 1 Patient disposition. AE,
adverse event.
McInnes IB, et al. Ann Rheum Dis 2014;73:349–356. doi:10.1136/annrheumdis-2012-202646 351
Clinical and epidemiological research
group.bmj.com on May 3, 2017 - Published by http://ard.bmj.com/Downloaded from 
Safety
The rate of adverse events (AEs) was numerically higher in secu-
kinumab versus placebo patients (26 (93%) vs 11 (79%),
respectively) (table 3). Six SAEs were reported in four secukinu-
mab patients: tendon rupture/carpal tunnel syndrome/cellulitis
of the hand in one patient (the cellulitis was treated surgically
and with cefuroxime 500 mg twice daily, with Staphylococcus
aureus reported as the causative agent); morbid obesity in one
patient (adapositas magna; diagnosed and treated with a surgical
procedure during the course of the study); fall in one patient;
and breast cancer in one patient (diagnosed prior to dosing, and
thus constituting a protocol violation). One SAE was reported
in a placebo recipient (polyarthritis; severe flare requiring hospi-
talisation). None of the SAEs were suspected by the investigators
to be related to the study treatment.
There were 35 episodes of infection (26 mild, 8 moderate,
1 severe) in 23 patients (16 (57%) secukinumab patients and
7 (50%) receiving placebo). Rates and types of infections were
comparable for secukinumab- and placebo-treated patients.
Events of leucopenia were observed in eight secukinumab
patients and one placebo patient, all Common Terminology
Criteria (CTC) Grade 1; neutropenia events were observed in
six secukinumab patients and one placebo patient (all CTC
Grade 1 except for one: CTC Grade 2 (1.5−1.0×109/l), occur-
ring 5 weeks after the second infusion), and no relationship
with concurrent infections was apparent. No other clinically
relevant alterations in laboratory parameters were reported,
with the exception of a single elevated liver function test in one
patient at week 24 (21 weeks after the last dosing with secukinu-
mab). No antibodies to secukinumab were detected during the
study up to week 24.
DISCUSSION
This is the first study to examine the effects of blockade of
IL-17A in a cohort of patients with active PsA. In 42 patients
with moderate-to-severe PsA with or without prior TNFi expos-
ure and with or without concomitant background DMARD
therapy, secukinumab was associated with numerically greater
Table 1 Demographics and baseline characteristics
Variables Secukinumab Placebo Total
Safety analysis set* (n=28) (n=14) (n=42)
Female, n (%) 19 (68) 8 (57) 27 (64)
Age (years), mean (SD) 46.7 (11.3) 47.6 (8.1) 47.0 (10.2)
Predominant race, n (%)
Caucasian 28 (100) 11 (79) 39 (93)
Other 0 (0.0) 3 (21) 3 (7)
BMI (kg/m2), mean (SD) 31.9 (8.1) 27.5 (4.9) 30.4 (7.5)
Efficacy analysis set* (n=24) (n=13) (n=37)
Tender joint count, mean (SD) 23.5 (19.4) 22.6 (11.0) 23.2 (16.8)
Swollen joint count, mean (SD) 8.3 (5.6) 9.5 (5.4) 8.7 (5.5)
CRP (mg/l), median (min–max) 4.9 (0.3–43) 6.2 (1.3–39.7) 5 (0.3–43)
ESR (mm/h), median (min–max) 23.0 (2–64) 14.0 (5–75) 22.0 (2–75)
DAS28, mean (SD) 4.8 (1.2) 4.8 (1.2) 4.8 (1.2)
LDI basic, mean (SD) 2.7 (2.32) 1.6 (2.34) 2.2 (2.30)
MASES, mean (SD) 3.0 (4.1) 3.4 (2.3) 3.1 (3.6)
SPARCC, mean (SD) 4.4 (5.06) 6.1 (4.41) 5.0 (4.84)
PASI, mean (SD) 3.5 (4.20) 2.4 (2.13) 3.1 (3.62)
PsA duration (years), mean (SD) 6.3 (6.8) 5.4 (3.8) 6.0 (5.9)
Oligoarticular, n (%) 10 (42) 4 (31) 14 (38)
Polyarticular, n (%) 13 (54) 9 (69) 22 (59)
Distal interphalangeal joint predominant, n (%) 1 (4) 0 (0) 1 (3)
Co-existing psoriasis, n (%) 23 (96) 11 (85) 34 (92)
Concomitant DMARDs, n (%) 13 (54) 6 (46) 19 (51)
MTX 12 (50) 6 (46) 18 (49)
Leflunomide 6 (25) 1 (8) 7 (19)
Chloroquine 1 (4) – 1 (3)
SSZ 2 (8) – 2 (5)
Concomitant NSAID, n (%) 18 (75) 1 (8) 19 (51)
Concomitant steroid, n (%) 8 (33) 2 (15) 10 (27)
Intra-articular† 2 (8) – 2 (5)
Intramuscular – 1 (8) 1 (3)
Oral 7 (29) 2 (15) 9 (24)
Topical 1 (4%) – 1 (3)
Prior TNFα inhibitor, n (%) 10 (42) 3 (23) 13 (35)
*The efficacy analysis set consisted of all patients who received the allocated treatment; the safety analysis set consisted of all patients who received at least one dose of the study
medication regardless of treatment assignment; tender and swollen joint counts were based on 68 and 66 joints, respectively.
†Protocol violations.
BMI, body mass index; CRP, C reactive protein; DAS, disease activity score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; LDI, Leeds Dactylitis
Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug; PASI, Psoriasis Area and Severity Index;
PsA, psoriatic arthritis; SPARCC, Spondyloarthritis Research Consortium of Canada; SSZ, sulphasalazine; TNF, tumour necrosis factor.
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ACR20 response rates compared with placebo, demonstrated a
favourable safety profile and was well tolerated. The frequencies
and types of AEs, including infections and SAEs, were compar-
able between the secukinumab and the placebo groups and were
consistent with the safety profile seen with secukinumab in
other indications, including larger studies of patients with psor-
iasis vulgaris and rheumatoid arthritis.15–18 32 While clear
trends towards beneficial clinical effects of secukinumab were
seen, the primary efficacy endpoint (difference in ACR20
response rates between secukinumab and placebo at week 6)
was not met.
However, several observations support the view that secukin-
umab might exert biologically relevant effects in PsA. The rate
of discontinuations was three times higher in the placebo group
compared with the secukinumab group. In addition, secondary
ACR response endpoints consistently showed numerically
greater responses for secukinumab compared with placebo, up
to and including week 24, indicating that the early effects
induced by secukinumab were also durable. QoL measures
demonstrated deteriorations of SF-36 physical component and
HAQ-DI scores in placebo patients, as compared with secukinu-
mab patients, who reported marked improvements over time.
Although this study was not powered to detect differences in
acute-phase parameters over time, a post hoc analysis showed
significant differences in the reductions of CRP and ESR
between secukinumab- and placebo-treated patients, particularly
Figure 2 ACR20, ACR50 and ACR70 response rates and PsARC rates over time for patients receiving secukinumab 10 mg/kg or matching placebo
(two intravenous injections, 21 days apart). *Week 24 or end of study if early discontinuation; data shown in the figure are mean (SD). ACR,
American College of Rheumatology; D, day; PsARC, Psoriatic Arthritis Response Criteria.
Table 2 Summary of percentage change from baseline in HAQ-DI and SF-36 physical component scores in patients receiving secukinumab
10 mg/kg or matching placebo (two intravenous injections, 21 days apart)
Secukinumab (N=24) Placebo (N=13) p Value
HAQ-DI*
Baseline, mean (SD) 1.64 (0.66) 1.20 (0.71)
Week 6, mean (SD) –20.6 (30.3) 0.25 (14.0) 0.002
Patients with reduction from baseline >0.3 (n/nT;† %) 7/20 (35.0%) 0/10 (0.0%) 0.038
Week 12, mean (SD) –27.94 (35.5) 6.34 (25.5) 0.004
Patients with reduction from baseline >0.3 (n/nT;† %) 9/21 (42.9%) 1/11 (9.1%) 0.056
Week 24/EOS, mean (SD) –19.68 (30.037) 17.09 (54.5) 0.019
Patients with reduction from baseline >0.3 (n/nT;† %) 9/23 (39.1%) 1/11 (9.1%) 0.077
SF-36 physical component score‡
Baseline, mean (SD) 30.8 (10.0) 36.1 (9.0)
Week 6, mean (SD) 15.2 (28.4) –0.51 (29.6) 0.030
Week 12, mean (SD) 20.4 (32.6) –3.25 (19.4) 0.037
Week 24/EOS, mean (SD) 15.2 (28.1) –2.61 (26.0) 0.148
*p value comparison is for mean changes from baseline, secukinumab versus placebo.
†n, number of subjects with HAQ-DI reduction from baseline >0.3; nT, total number of subjects at visit with non-missing HAQ-DI values at baseline and at visit.
‡p value comparison is for mean changes from baseline, secukinumab versus placebo (mixed-effect model).
EOS, end of study; HAQ-DI, Health Assessment Questionnaire Disability Index; SF-36, Short Form Health Survey.
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among secukinumab patients with elevations in pre-treatment
levels. It is also worth noting that preliminary results have sug-
gested secukinumab was effective in reducing symptoms of
moderate-to-severe active ankylosing spondylitis, another form
of spondyloarthritis.16
Limitations of our study that may have affected the ability to
meet the primary endpoint include the small sample size and
the preliminary dosing regimen of only two intravenous infu-
sions. The study may also have been underpowered to achieve
statistical significance with the chosen sample size and primary
endpoint. It should also be noted that CRP levels, QoL mea-
sures, and enthesitis and PASI scores at entry were generally
lower than those seen in previous studies of TNF inhibitors in
combination with other treatments,33–37 suggesting that efficacy
in this trial might be underestimated because of lesser disease
activity or severity in our study population.
In a post hoc subgroup analysis, the ACR20 response rate at
week 6 among secukinumab-treated patients in the TNFi pre-
exposed subgroup was lower than that observed for placebo
recipients in the TNFi pre-exposed subgroup, whereas the
response rate for secukinumab among TNFi-naive patients was
substantially greater than that reported for placebo recipients in
either the TNFi-naive or the TNFi pre-exposed subgroup. Since
the sample size of these subgroups was very small, these findings
require further study in a larger patient cohort.
The notion that secukinumab treatment resulted in a bio-
logical effect in PsA patients is supported by the observed
decrease in hBD-2 serum levels after active treatment with secu-
kinumab compared with placebo; hBD-2 is an important down-
stream marker of the IL-17 pathway. This observation is in line
with reports of hBD-2 as an important innate inflammatory
marker in active plaque psoriasis13 and its top rank in the
Figure 3 (A) Levels of acute-phase reactants (CRP and ESR) and human β-defensin-2 (hBD-2) over time in patients receiving secukinumab
10 mg/kg (two intravenous injections, 21 days apart). (B) Levels of CRP, ESR and hBD-2 over time in patients receiving matching placebo. (C) ACR20,
ACR50 and ACR70 response rates at week 6 for TNFα inhibitor (TNFi)-naive versus TNFi pre-exposed patients by treatment group. ACR, American
College of Rheumatology; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; TNFα, tumour necrosis factor α.
Table 3 Summary of safety events (safety population)*
Variable, n (%) Secukinumab (n=28) Placebo (n=14)
Any AE 26 (92.9) 11 (78.6)
SAEs 4 (14.3) 1 (7.1)
Most common AEs†
Nasopharyngitis 7 (25.0) 5 (35.7)
Headache 6 (21.4) 1 (7.1)
Nausea 4 (14.3) 1 (7.1)
Dizziness 4 (14.3) 0 (0.0)
Fatigue 3 (10.7) 0 (0.0)
Diarrhoea 3 (10.7) 1 (7.1)
Pruritus 3 (10.7) 1 (7.1)
Myalgia 3 (10.7) 0 (0.0)
Cough 3 (10.7) 0 (0.0)
Vertigo 1 (3.6) 3 (21.4)
*Data for safety population (all patients who received the study medication regardless
of treatment assignment).
†Only AEs occurring in three or more patients in any group are presented.
AE, adverse event; SAE, serious adverse event.
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IL-17A gene signature.12 Although it was shown previously that
hBD-2 mRNA is significantly downregulated in lesional skin of
psoriasis patients upon blockade with etanercept14 and secukin-
umab,15 the relative contribution of keratinocyte-derived and,
hypothetically, joint epithelium-derived hBD-2 in PsA requires
further study.
A recent report suggested that the synovial tissue in PsA is
enriched with IL-17R, and that the receptor IL-17RA is func-
tionally active in PsA.8 It remains to be established whether
IL-17A blockade by secukinumab has an impact on IL-17RA
expression and function in the synovium. It is also possible that
other IL-17 family members could play a role in mediating the
PsA disease process in affected tissues; further research will be
needed to determine whether secukinumab has specificity for all
relevant members of this cytokine family.
Ustekinumab, an anti-IL-12/-23 p40 antibody registered for
the treatment of psoriasis, showed preliminary efficacy in a
phase II trial of patients with PsA.38 It is possible that the effects
of ustekinumab are in part mediated by inhibition of IL-17A,
which acts downstream of IL-23.39 A confirmatory phase III
study of ustekinumab in active PsA is ongoing (ClinicalTrials.gov
trial NCT01009086; accessed 4 December 2012).
In conclusion, secukinumab was well tolerated and demon-
strated preliminary evidence for potential therapeutic benefit in
patients with moderate-to-severe PsA. Larger studies are required
to confirm results obtained from this initial phase II cohort.
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